<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The adverse effects of regimes in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment have forced us to change to new targeted therapy options </plain></SENT>
<SENT sid="1" pm="."><plain>Understanding these side effects, which can lead to discontinuation of the new therapy strategies, will allow the clinical management of these side effects and result in continuing therapies with effective medications </plain></SENT>
<SENT sid="2" pm="."><plain>Bevacizumab, which is an IgG1 antibody against vascular endothelial growth factor, has side effects such as <z:hpo ids='HP_0000093'>proteinuria</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, venous and arterial <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo>, and <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>This is the first reported case of dural sinus vein <z:mp ids='MP_0005048'>thrombosis</z:mp>, during the treatment with bevacizumab </plain></SENT>
</text></document>